# Evaluation of the Bioavailability of Pramlintide

> **NCT00042471** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 75 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Pramlintide acetate

## Key facts

- **NCT ID:** NCT00042471
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042471, "Evaluation of the Bioavailability of Pramlintide". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00042471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*